Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Phase 4 – monitoring after market approval
Conditions:
Staphylococcus Aureus Septicemia
Staphylococcus Aureus Bacteremia
S. Aureus Bacteremia
S. Aureus Bloodstream Infection
Staphylococcus Aureus Endocarditis
Sponsor: Todd C. Lee MD MPH FIDSA
trial.available_in:
БГ
Overview
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Who can participate
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion Criteria:
* Methicillin-resistant S. aureus bacteremia
Exclusion Criteria:
* Severe allergy or non-severe rash to vancomycin or daptomycin
* Suspected or confirmed MRSA pneumonia
* Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
БГ